- Home
- ALVR vs TLSA Comparison
ALVR vs TLSA Comparison
Compare ALVR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- TLSA
- Stock Information
- Founded
- ALVR 2013
- TLSA 2013
- Country
- ALVR United States
- TLSA United Kingdom
- Employees
- ALVR N/A
- TLSA N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- TLSA Health Care
- Exchange
- ALVR Nasdaq
- TLSA Nasdaq
- Market Cap
- ALVR 87.7M
- TLSA 87.8M
- IPO Year
- ALVR 2020
- TLSA 2000
- Fundamental
- Price
- ALVR $0.94
- TLSA $1.19
- Analyst Decision
- ALVR Sell
- TLSA
- Analyst Count
- ALVR 5
- TLSA 0
- Target Price
- ALVR $1.00
- TLSA N/A
- AVG Volume (30 Days)
- ALVR 155.6K
- TLSA 145.8K
- Earning Date
- ALVR 11-04-2024
- TLSA 05-10-2024
- Dividend Yield
- ALVR N/A
- TLSA N/A
- EPS Growth
- ALVR N/A
- TLSA N/A
- EPS
- ALVR N/A
- TLSA N/A
- Revenue
- ALVR N/A
- TLSA N/A
- Revenue This Year
- ALVR N/A
- TLSA N/A
- Revenue Next Year
- ALVR N/A
- TLSA N/A
- P/E Ratio
- ALVR N/A
- TLSA N/A
- Revenue Growth
- ALVR N/A
- TLSA N/A
- 52 Week Low
- ALVR $0.58
- TLSA $0.41
- 52 Week High
- ALVR $2.49
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- TLSA 65.44
- Support Level
- ALVR $0.74
- TLSA $0.83
- Resistance Level
- ALVR $0.91
- TLSA $0.92
- Average True Range (ATR)
- ALVR 0.06
- TLSA 0.09
- MACD
- ALVR 0.01
- TLSA 0.03
- Stochastic Oscillator
- ALVR 94.50
- TLSA 84.52
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.